U.S. Markets close in 1 hr 5 mins

CEL-SCI Corporation (CVM)

NYSE MKT - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.5701-0.1589 (-5.8226%)
As of 2:54PM EDT. Market open.
People also watch
Full screen
Previous Close2.7290
Bid2.5600 x 400
Ask2.5800 x 800
Day's Range2.5200 - 2.6600
52 Week Range0.0600 - 3.6900
Avg. Volume1,867,985
Market Cap23.95M
PE Ratio (TTM)-1.54
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend Date1996-08-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

    The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

  • Associated Press7 days ago

    Cel-Sci reports 3Q loss

    On a per-share basis, the Vienna, Virginia-based company said it had a loss of 53 cents. The cancer immunotherapy company posted revenue of $17,400 in the period. Its adjusted revenue was $17,000. In the ...

  • CEL-SCI Corp. :CVM-US: Earnings Analysis: Q2, 2017 By the Numbers : June 19, 2017
    Capital Cube2 months ago

    CEL-SCI Corp. :CVM-US: Earnings Analysis: Q2, 2017 By the Numbers : June 19, 2017

    Categories: Yahoo FinanceGet free summary analysis CEL-SCI Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CEL-SCI Corp. – Curis, Inc., BioCryst Pharmaceuticals, Inc., Amgen Inc., Xencor, Inc., CytRx Corporation, Johnson & Johnson, Vical Incorporated, Teva Pharmaceutical Industries Limited Sponsored ADR and Emergent BioSolutions Inc. ... Read more (Read more...)